159 related articles for article (PubMed ID: 27436896)
21. N-acetylcysteine modulates glutamatergic dysfunction and depressive behavior in Huntington's disease.
Wright DJ; Gray LJ; Finkelstein DI; Crouch PJ; Pow D; Pang TY; Li S; Smith ZM; Francis PS; Renoir T; Hannan AJ
Hum Mol Genet; 2016 Jul; 25(14):2923-2933. PubMed ID: 27179791
[TBL] [Abstract][Full Text] [Related]
22. Neurodegeneration in Huntington's disease involves loss of cystathionine γ-lyase.
Paul BD; Snyder SH
Cell Cycle; 2014; 13(16):2491-3. PubMed ID: 25486189
[No Abstract] [Full Text] [Related]
23. Increased Steady-State Mutant Huntingtin mRNA in Huntington's Disease Brain.
Liu W; Chaurette J; Pfister EL; Kennington LA; Chase KO; Bullock J; Vonsattel JP; Faull RL; Macdonald D; DiFiglia M; Zamore PD; Aronin N
J Huntingtons Dis; 2013; 2(4):491-500. PubMed ID: 25062733
[TBL] [Abstract][Full Text] [Related]
24. Nucleocytoplasmic trafficking and transcription effects of huntingtin in Huntington's disease.
Truant R; Atwal RS; Burtnik A
Prog Neurobiol; 2007 Nov; 83(4):211-27. PubMed ID: 17240517
[TBL] [Abstract][Full Text] [Related]
25. Quantitative proteomic analysis of induced pluripotent stem cells derived from a human Huntington's disease patient.
Chae JI; Kim DW; Lee N; Jeon YJ; Jeon I; Kwon J; Kim J; Soh Y; Lee DS; Seo KS; Choi NJ; Park BC; Kang SH; Ryu J; Oh SH; Shin DA; Lee DR; Do JT; Park IH; Daley GQ; Song J
Biochem J; 2012 Sep; 446(3):359-71. PubMed ID: 22694310
[TBL] [Abstract][Full Text] [Related]
26. Gamma-tocopheryl quinone, not alpha-tocopheryl quinone, induces adaptive response through up-regulation of cellular glutathione and cysteine availability via activation of ATF4.
Ogawa Y; Saito Y; Nishio K; Yoshida Y; Ashida H; Niki E
Free Radic Res; 2008 Jul; 42(7):674-87. PubMed ID: 18654882
[TBL] [Abstract][Full Text] [Related]
27. Activating transcription factor 4-dependent induction of FGF21 during amino acid deprivation.
De Sousa-Coelho AL; Marrero PF; Haro D
Biochem J; 2012 Apr; 443(1):165-71. PubMed ID: 22233381
[TBL] [Abstract][Full Text] [Related]
28. Effects of chronic stress on the onset and progression of Huntington's disease in transgenic mice.
Mo C; Renoir T; Hannan AJ
Neurobiol Dis; 2014 Nov; 71():81-94. PubMed ID: 25088714
[TBL] [Abstract][Full Text] [Related]
29. Novel BAC Mouse Model of Huntington's Disease with 225 CAG Repeats Exhibits an Early Widespread and Stable Degenerative Phenotype.
Wegrzynowicz M; Bichell TJ; Soares BD; Loth MK; McGlothan JS; Mori S; Alikhan FS; Hua K; Coughlin JM; Holt HK; Jetter CS; Pomper MG; Osmand AP; Guilarte TR; Bowman AB
J Huntingtons Dis; 2015; 4(1):17-36. PubMed ID: 26333255
[TBL] [Abstract][Full Text] [Related]
30. Transcription factor ATF4 directs basal and stress-induced gene expression in the unfolded protein response and cholesterol metabolism in the liver.
Fusakio ME; Willy JA; Wang Y; Mirek ET; Al Baghdadi RJ; Adams CM; Anthony TG; Wek RC
Mol Biol Cell; 2016 May; 27(9):1536-51. PubMed ID: 26960794
[TBL] [Abstract][Full Text] [Related]
31. The role of iron imaging in Huntington's disease.
van den Bogaard SJ; Dumas EM; Roos RA
Int Rev Neurobiol; 2013; 110():241-50. PubMed ID: 24209441
[TBL] [Abstract][Full Text] [Related]
32. Proteomics of Huntington's disease-affected human embryonic stem cells reveals an evolving pathology involving mitochondrial dysfunction and metabolic disturbances.
McQuade LR; Balachandran A; Scott HA; Khaira S; Baker MS; Schmidt U
J Proteome Res; 2014 Dec; 13(12):5648-59. PubMed ID: 25316320
[TBL] [Abstract][Full Text] [Related]
33. Antisense oligonucleotide-mediated correction of transcriptional dysregulation is correlated with behavioral benefits in the YAC128 mouse model of Huntington's disease.
Stanek LM; Yang W; Angus S; Sardi PS; Hayden MR; Hung GH; Bennett CF; Cheng SH; Shihabuddin LS
J Huntingtons Dis; 2013; 2(2):217-28. PubMed ID: 25063516
[TBL] [Abstract][Full Text] [Related]
34. Study of oxidative damage and antioxidant systems in two Huntington's disease rodent models.
Pérez-Severiano F; Montes S; Gerónimo-Olvera C; Segovia J
Methods Mol Biol; 2013; 1010():177-200. PubMed ID: 23754226
[TBL] [Abstract][Full Text] [Related]
35. Retinal dysfunction, photoreceptor protein dysregulation and neuronal remodelling in the R6/1 mouse model of Huntington's disease.
Batcha AH; Greferath U; Jobling AI; Vessey KA; Ward MM; Nithianantharajah J; Hannan AJ; Kalloniatis M; Fletcher EL
Neurobiol Dis; 2012 Mar; 45(3):887-96. PubMed ID: 22198376
[TBL] [Abstract][Full Text] [Related]
36. Transcriptional dysregulation of coding and non-coding genes in cellular models of Huntington's disease.
Bithell A; Johnson R; Buckley NJ
Biochem Soc Trans; 2009 Dec; 37(Pt 6):1270-5. PubMed ID: 19909260
[TBL] [Abstract][Full Text] [Related]
37. Oxidative damage in Huntington's disease pathogenesis.
Browne SE; Beal MF
Antioxid Redox Signal; 2006; 8(11-12):2061-73. PubMed ID: 17034350
[TBL] [Abstract][Full Text] [Related]
38. Modulation of energy deficiency in Huntington's disease via activation of the peroxisome proliferator-activated receptor gamma.
Chiang MC; Chen CM; Lee MR; Chen HW; Chen HM; Wu YS; Hung CH; Kang JJ; Chang CP; Chang C; Wu YR; Tsai YS; Chern Y
Hum Mol Genet; 2010 Oct; 19(20):4043-58. PubMed ID: 20668093
[TBL] [Abstract][Full Text] [Related]
39. Beyond the redox imbalance: Oxidative stress contributes to an impaired GLUT3 modulation in Huntington's disease.
Covarrubias-Pinto A; Moll P; Solís-Maldonado M; Acuña AI; Riveros A; Miró MP; Papic E; Beltrán FA; Cepeda C; Concha II; Brauchi S; Castro MA
Free Radic Biol Med; 2015 Dec; 89():1085-96. PubMed ID: 26456058
[TBL] [Abstract][Full Text] [Related]
40. Mass Spectrometry Analysis of Wild-Type and Knock-in Q140/Q140 Huntington's Disease Mouse Brains Reveals Changes in Glycerophospholipids Including Alterations in Phosphatidic Acid and Lyso-Phosphatidic Acid.
Vodicka P; Mo S; Tousley A; Green KM; Sapp E; Iuliano M; Sadri-Vakili G; Shaffer SA; Aronin N; DiFiglia M; Kegel-Gleason KB
J Huntingtons Dis; 2015; 4(2):187-201. PubMed ID: 26397899
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
